Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $172,636.60 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 6,995 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.68, for a total value of $172,636.60. Following the completion of the sale, the chief financial officer directly owned 86,896 shares of the company’s stock, valued at approximately $2,144,593.28. This represents a 7.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total value of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total value of $90,545.00.

Kestra Medical Technologies Trading Up 0.8%

Shares of NASDAQ KMTS traded up $0.21 during trading on Thursday, hitting $25.27. 184,867 shares of the company were exchanged, compared to its average volume of 393,651. The company has a fifty day moving average price of $22.86 and a 200-day moving average price of $22.54. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. On average, equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at about $31,000. Russell Investments Group Ltd. boosted its holdings in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after acquiring an additional 474 shares during the period. BNP Paribas Financial Markets grew its position in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Kestra Medical Technologies in the 4th quarter valued at $72,000. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. BTIG Research increased their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. The Goldman Sachs Group reduced their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of “Hold” and an average target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.